Larry Biegelsen

“Tom, I don't want to take away from the strong quarter here, but, you know, in the Q3 calls, You've typically given some helpful color on the following year.”

“Kevin, just to follow up on the revenue guidance, the organic growth needs to be about 11%, I think, in the second half to reach the midpoint of the guidance.”

“And yeah, pretty impressive quarter here, guys. So I'll be the first to ask about the IDOS LCD. So, you know, since the open meetings for the IDOS LCD, how has your confidence in the revised policy changed?”

“Mike, regarding Watchmen, I think you said mid to high single-digit decline in the second half of 26. So when you say no improvement in 27, are you referring to the full-year guide of flat to low single-digit growth or second-half guidance?”

“And, yeah, maybe the other point for Japan specifically is we have national reimbursement, but we have to work through a contracting process, hospital by hospital. and while we do make significant and have made significant progress in q2 that's a gating item and it's just something that the team will need to continue…”